SEC Form 4 · accession 0002001011-26-000102
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John L Lamattina
Director
Period of report
Jun 10, 2026
Accepted (ET)
Jun 12, 2026 · 5:26 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 10, 2026 | S | 257 | $247.2237 | D | 31,303 | D | |
| Common StockF2 | Jun 10, 2026 | S | 232 | $248.1111 | D | 31,071 | D | |
| Common StockF3 | Jun 10, 2026 | S | 697 | $249.5326 | D | 30,374 | D | |
| Common StockF4 | Jun 10, 2026 | S | 3,405 | $251.6158 | D | 26,969 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $246.6300 to $247.6100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $247.9400 to $248.3350. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $249.3400 to $250.2700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $250.9100 to $251.8950. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.